2022
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER
Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBenzhydryl CompoundsBlood PressureFemaleHeart FailureHumansMaleMiddle AgedStroke VolumeConceptsSystolic blood pressureBlood pressureHeart failureSBP categoriesEjection fractionPrimary outcomeKansas City Cardiomyopathy Questionnaire total symptom scoreTreatment effectsSodium-glucose cotransporter 2 inhibitorsBaseline systolic blood pressureBlood pressure-lowering effectHigher systolic blood pressureHigher heart failureClass I recommendationCotransporter 2 inhibitorsPressure-lowering effectTotal symptom scoreCardiovascular outcomesAdverse eventsAntihypertensive effectSecondary outcomesStroke riskI recommendationSymptom scoresCardiovascular disease
2001
The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy
Novella S, Inzucchi S, Goldstein J. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle & Nerve 2001, 24: 1229-1231. PMID: 11494278, DOI: 10.1002/mus.1137.Peer-Reviewed Original ResearchConceptsIdiopathic sensory neuropathyAbnormal glucose metabolismUndiagnosed abnormal glucose metabolismPainful symptomsSensory neuropathyGlucose metabolismOral glucose tolerance testComparison of patientsGlucose tolerance testUndiagnosed diabetesGlucose toleranceTolerance testPatientsNeuropathySymptomsP-valueMetabolismDiabetesHigh frequency